Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Successfully Strategize Real World Evidence For Market Access

Executive Summary

Payers and clinicians increasingly want to know how products work in real life, especially when data is limited. Real world evidence can help companies argue a product's value, but they should think carefully about their strategies as challenges remain.

You may also be interested in...



Efficacy Studies Not Enough? Consider GSK's Salford Lung Study As New Model

Full results from asthma patients included in the Salford Lung Study provide powerful support for the use of “real world” effectiveness studies as a more relevant form of evidence to inform prescribing choices and improve patient outcomes, particularly in what turned out to be a general population of asthmatics that were still suffering symptoms under usual care.

Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?

Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.

Q&A: Pfizer On Unlocking The Promise Of Real World Evidence

Real world evidence offers big potential to get medicines to the market, but exploiting the data is not always easy for companies. Pfizer's James Harnett explains the firm's RWE strategy and some of the challenges, like unstructured data and the need for incentives and standards for gathering the data.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel